Genetic factors contribute to patient-specific warfarin dose for Han Chinese

Clinica Chimica Acta

Volumn 396, Issue 1-2, 2008, Pages 76-79

  Wang, Ting Liang ^a,b   Li, Hong Lei ^a,b   Tjong, Wen Ye ^a   Chen, Qian Su ^c   Wu, Guan Sheng ^c   Zhu, Hai Tao ^c   Hou, Zi Shan ^d   Xu, Shu ^d   Ma, Sheng Jun ^e   Wu, Madeline ^b   Tai, Susan ^a  

^a Mochtar Riady Institute for Nanotechnology   (Indonesia)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^c GUIZHOU MEDICAL UNIVERSITY   (China)

^d LINYI PEOPLE'S HOSPITAL   (China)

^e LIAOCHENG PEOPLE'S HOSPITAL   (China)

Author keywords

Chinese; CYP2C9; EPHX1; SNP; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; EPOXIDE HYDROLASE; GENE PRODUCT; OROSOMUCOID; OROSOMUCOID 1; OROSOMUCOID 2; PROTEIN C; UNCLASSIFIED DRUG; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADULT; AGED; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; BODY WEIGHT; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; ETHNICITY; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT INDICATION;

ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SUBSTRATE SPECIFICITY; THROMBOSIS; WARFARIN;

EID: 50249160170     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.07.005     Document Type: Article

References (32)

1. Daly A.K., and King B.P. Pharmacogenetics of oral anticoagulants. Pharmacogenenetics 13 (2003) 247-252
2. Landefeld C.S., and Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 95 (1993) 315-328
3. Aithal G.P., Day C.P., Kesteven P.J., and Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirements and risk of bleeding complication. Lancet 353 (1999) 717-719
4. Geisen C., Watzka M., Sittinger K., et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94 (2005) 773-779
5. Voora D., Eby C., Linder M.W., et al. Prospective dosing of warfarin based on the cytochrome P-450 2C9 genotype. Thromb Haemost 93 (2005) 700-705
6. Sanderson S., Emery J., and Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7 (2005) 97-104
7. Bell R.G., Sadowski J.A., and Matschiner J.T. Mechanism of action of warfarin. Warfarin and metabolism of vitamin K 1. Biochemistry 11 (1972) 1959-1961
8. Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 257 (2005) 209-223
9. Rost S., Fregin A., Ivaskevicius V., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type2. Nature 427 (2004) 537-541
10. Li T., Chang C.Y., Jin D.Y., Lin P.J., Khvorova A., and Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427 (2004) 541-544
11. D'Andrea G., D'Ambrosio R.L., Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2005) 645-649
12. Yuan H.Y., Chen J.J., Lee M.T., et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14 (2005) 1745-1751
13. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 (2005) 2285-2293
14. Rettie A.E., Korzekwa K.R., Kunze K.L., et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5 (1992) 54-59
15. Rettie A.E., Wienkers L.C., Gonzalez F.J., Trager W.F., and Korzekwa K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4 (1994) 39-42
16. Mushiroda T., Qhnishi Y., Saito S., et al. Association of VKORC1 and CYP2C9 polymorohisms with warfarin dose requirements in Japanese patients. J Hum Genet 51 (2006) 249-253
17. Miao L.Y., Yang J., Huang C., and Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 63 (2007) 1135-1141
18. Wadelius M., Chen L.Y., Eriksson N., et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121 (2007) 23-34
19. Takahashi H., Wilkinson G.R., Caraco Y., et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Paharmacal Ther 73 (2003) 253-263
20. Kirchheiner J., and Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77 (2005) 1-16
21. Chern H.D., Ueng T.H., Fu Y.P., and Cheng C.W. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. Clin Chim Acta 367 (2006) 108-113
22. Caldwell M.D., Awad T., Johnson J.A., et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111 (2008) 4106-4112
23. Wadelius M., and Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7 (2007) 99-111
24. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype map. Bioinformatics 21 (2005) 263-265
25. Wadelius M., Chen L.Y., Downes K., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5 (2005) 262-270
26. Chen L.Y., Eriksson N., Gwilliam R., Bentley D., Deloukas P., and Wadelius M. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood 106 (2005) 3673-3674
27. Liao L.H., Zhang H., Lai M.P., et al. The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese. Clin Chim Acta 380 (2007) 191-196
28. Furuya H., Fernandez-Salguero P., Gregory W., et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5 (1995) 389-392
29. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6 (1996) 341-349
30. Haining R.L., Hunter A.P., Veronese M.E., Trager W.F., and Rettie A.E. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 333 (1996) 447-458
31. Kimura M., Ieiri I., Mamiya K., Urae A., and Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 20 (1998) 243-247
32. Yu B.N., Luo C.H., Wang D., et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 348 (2004) 57-61